secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001104659-24-038444
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Pharma FY2023 PEDMARK sales $21.3M, Q4 net loss $2.7M; $43M licensing deal bolsters cash
--------------------------------------------------------------------------------

- FY2023 PEDMARK net product sales $21.3M (vs $1.5M in 2022); Q4 net sales $9.7M.
- Net loss for FY2023 $16.0M ($0.60 per share) vs $23.7M ($0.90) in 2022; Q4 net loss $2.7M ($0.10).
- Cash and equivalents $13.2M at Dec 31, 2023; pro forma cash >$55M after receiving ~$43M upfront from Norgine licensing deal.
- Entered exclusive licensing agreement with Norgine for PEDMARQSI in Europe, Australia, NZ; potential up to ~$230M milestones plus tiered royalties.
- FDA issued public reminder that PEDMARK is not substitutable with other sodium thiosulfate products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/0001104659-24-038444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/tm249737d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer